Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PRF1 | P14222 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19414841 | 0.88 | MAOA (0.74) | MAOAPARP1MAOBMAPT | |
| SCHEMBL19414843 | 0.85 | MAOA (0.59) | MAOAPARP1MAOBMAPTGAA | |
| SCHEMBL25421184 | 0.79 | KCNJ1 (0.52) | MAOAKCNJ1KCNH2MAOBMAPT | |
| SCHEMBL1656137 | 0.78 | MAOA (0.60) | MAOAKCNJ1KCNH2MAOBMAPT | |
| SCHEMBL13870507 | 0.74 | KCNJ1 (0.60) | MAOAKCNJ1KCNH2MAOBMAPT | |
| SCHEMBL31135367 | 0.74 | KCNJ1 (0.60) | MAOAKCNJ1KCNH2MAOBMAPT | |
| SCHEMBL13554892 | 0.74 | KCNJ1 (0.60) | MAOAKCNJ1KCNH2MAOBMAPT | |
| SCHEMBL29861325 | 0.74 | PRF1 (0.65) | MAOAKCNJ1KCNH2MAOBMAPT | |
| SCHEMBL1702314 | 0.74 | PRF1 (0.65) | MAOAKCNJ1KCNH2MAOBMAPT | |
| SCHEMBL26994676 | 0.74 | MAOA (0.59) | MAOAKCNJ1KCNH2MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889590-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-01-12 | — | — | US | disclosed |
| US-10233192-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180065976-A1 | DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-03-08 | — | — | US | disclosed |
| US-9777013-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233192-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | UNC119, UNC93B1, RIOX2 | MAOA 3450/4885PARP1 2470/4885KCNJ1 4454/4885 |
| US-10889590-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | UNC119, UNC93B1, RIOX2 | MAOA 3450/4885PARP1 2470/4885KCNJ1 4454/4885 |
| US-20180065976-A1 | DERIVATIVES OF UNCIALAMYCIN, METHODS OF SYNTHESIS AND THEIR USE AS ANTITUMOR AGENTS | UNC119, UNC93B1, RIOX2 | MAOA 3450/4885PARP1 2470/4885KCNJ1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.